Original articleImpact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study
Introduction
Restless legs syndrome (RLS) is a sensorimotor disorder [1] characterized by an urge or need to move the limbs, usually associated with abnormal sensations in the legs. These symptoms are worse at rest, are relieved by movement, and mainly occur in the evening and/or at night [2], [3], [4]. RLS was probably first described in the 17th century [5], but modern interest in the condition began with the work of Ekbom in the 1940s [6]. RLS morbidity in patients involves significant sleep disturbance and negative impact on quality of life [7]. The current understanding of the pathophysiology of RLS suggests the involvement of iron metabolism and dopaminergic dysfunction [1], [7].
Epidemiological studies indicate that the symptoms of RLS are present in about 5–10% of the general population [8], [9], [10]. Despite this high frequency of affected individuals, experience suggests that it is often undiagnosed in those who present for treatment [7]. It follows that there is a need to understand more about RLS and how it is likely to present in a medical practice.
The objective of the RLS epidemiology, symptoms, and treatment (REST) Primary Care study was to survey the diagnosis, impact, and treatment of clinically significant symptoms of RLS in an international primary care population. REST Primary Care is the first study to provide a matched view of RLS from both patient and physician perspectives. A unique feature of the study design is the opportunity to compare the responses of physicians and patients to questions on the presentation and management of RLS symptoms within the primary care population.
Section snippets
Methods
Primary care centers in the USA and four European countries participated in this study. The goal was to obtain similar numbers of respondents from each country. Data were obtained from 182 primary care physicians (PCPs) and 23,052 patients, as follows: France (59 PCPs/4808 patients); Germany (32/6723); Spain (30/5752); UK (28/2114); USA (33/3655). As practices in France are smaller, more PCPs were selected from France than from other countries. Physicians were recruited from all regions of each
Prevalence of RLS symptoms in a primary care population
The prevalence of any degree of RLS symptoms was 11.1% (2564/23,052) and that for symptoms at least once weekly was 9.6% (2223/23,052). Considering only patients with matched questionnaires, a minimum estimate of the prevalence in those with at least twice-weekly symptoms is 3.9% (899/23,052; Fig. 1) and in those whose symptoms have also appreciable negative impact on quality of life, 2.4% (551/23,052; Fig. 1). Figures for individual countries are given in Table 4.
Because there were 666
Discussion
The REST Primary Care study indicates that RLS is a common cause of sleep disruption that usually remains undiagnosed in primary care. Even when diagnosed, RLS is often not appropriately treated. These results highlight the need for education to make physicians more aware of how RLS presents and how it is diagnosed as well as the medications established to be most effective for its treatment. REST Primary Care is the first profile study of RLS to collect data on the condition from both the
Conclusions
In conclusion, the results of the REST Primary Care study suggest that RLS is a major cause of sleep disturbance among patients visiting PCPs in western Europe and the USA. The data reported here support the view that moderately severe symptoms of RLS causing appreciable distress are present in about 3% of patients visiting a PCP, but RLS often remains undiagnosed. Awareness of the condition appears to be low as shown by the wide range of diagnoses given to those with symptoms of RLS and by the
Acknowledgements
We would like to thank Trevor Brown of Premark, Inc. for his assistance in organizing the study, and Insight International Research with supervision by Nicola Cowland for carrying out the survey in all countries. Funds for the study were provided by GlaxoSmithKline.
References (26)
- et al.
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health
Sleep Med
(2003) - et al.
Quantitative criteria for insomnia
Behav Res Ther
(2003) - et al.
Prevalence of restless legs syndrome and periodic limb movement disorder in the general population
J Psychosom Res
(2002) - et al.
Restless legs syndrome in 218 patients: associated disorders
Sleep Med
(2000) Restless legs syndrome: a sensorimotor disorder of sleep/wake motor regulation
Curr Neurol Neurosci Rep
(2002)Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group
Mov Disord
(1995)- et al.
Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome
Sleep
(1999) De animae brutorum
(1672)Restless legs
Acta Med Scand Suppl
(1945)- et al.
Restless legs syndrome: a review of clinical and pathophysiologic features
J Clin Neurophysiol
(2001)
Epidemiology of restless legs symptoms in adults
Arch Intern Med
Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms
Mov Disord
Restless legs syndrome among working-aged women
Eur Neurol
Cited by (572)
Restless legs syndrome is prevalent in adults with cystic fibrosis and impacts sleep quality
2023, Journal of Cystic FibrosisSleep, neurocognition, and aging, including secular trends in older adult sleep
2021, Handbook of the Psychology of AgingSex and Sleep Disruption as Contributing Factors in Alzheimer's Disease
2024, Journal of Alzheimer's DiseaseSex and Sleep Disruption as Contributing Factors in Alzheimer's Disease
2024, Advances in Alzheimer's Disease